Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Systemic vasculitis associated with anti-neutrophil cytoplasmic antibodies against bactericidal/permeability increasing protein.

Fukuhara A, Tanino Y, Sato S, Ishii T, Nikaido T, Kanazawa K, Saito J, Ishida T, Kanno M, Watanabe T, Munakata M.

Intern Med. 2013;52(10):1095-9.

2.

Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis.

Sedivá A, Bartůnková J, Kolárová I, Hrusák O, Vávrová V, Macek M Jr, Lockwood CM, Dunn AC.

J Autoimmun. 1998 Apr;11(2):185-90.

PMID:
9650098
3.

The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies.

Schultz H, Weiss J, Carroll SF, Gross WL.

J Leukoc Biol. 2001 Apr;69(4):505-12. Review.

PMID:
11310835
6.

Bronchiectasis with myeloperoxidase antineutrophil cytoplasmic antibody and bactericidal/permeability-increasing protein antineutrophil cytoplasmic antibody.

Matsuyama W, Wakimoto J, Watanabe A, Kubota I, Hirotsu Y, Mizoguchi A, Iwami F, Kawabata M, Osame M.

Intern Med. 1999 Oct;38(10):813-6.

7.
8.

Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA).

Talor MV, Stone JH, Stebbing J, Barin J, Rose NR, Burek CL.

Clin Exp Immunol. 2007 Oct;150(1):42-8.

9.

Anti-neutrophil cytoplasmic autoantibodies against bactericidal/permeability-increasing protein in patients with rheumatoid arthritis and their correlation with bronchial involvement.

Wada Y, Kuroda T, Murasawa A, Nakano M, Narita I.

Mod Rheumatol. 2010 Jun;20(3):252-6. doi: 10.1007/s10165-009-0270-1.

PMID:
20107854
10.

Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.

Walmsley RS, Zhao MH, Hamilton MI, Brownlee A, Chapman P, Pounder RE, Wakefield AJ, Lockwood CM.

Gut. 1997 Jan;40(1):105-9.

12.

Extracapillary glomerulonephritis type I with the coexistence of positive anti-GBM and p-ANCA antibodies.

Toledo Perdomo K, Ortega Salas R, Pérez-Sáez MJ, Esquivias de Motta E, Espinosa Hernández M, López Andreu M, López Rubio F, Aljama García P.

Nefrologia. 2011;31(1):113-5. doi: 10.3265/Nefrologia.pre2010.Oct.10611. No abstract available.

14.

Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance.

Vecchi M, Sinico A, Bianchi MB, Radice A, Gionchetti P, Campieri M, de Franchis R.

Scand J Gastroenterol. 1998 Dec;33(12):1284-8.

PMID:
9930392
15.

Analysis of anti-neutrophil cytoplasmic antibodies (ANCA): frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects.

Audrain MA, Sesboüé R, Baranger TA, Elliott J, Testa A, Martin JP, Lockwood CM, Esnault VL.

Nephrol Dial Transplant. 2001 Jan;16(1):39-44.

16.

Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease.

Mahadeva R, Dunn AC, Westerbeek RC, Sharples L, Whitehouse DB, Carroll NR, Ross-Russell RI, Webb AK, Bilton D, Lomas DA, Lockwood CM.

Clin Exp Immunol. 1999 Sep;117(3):561-7.

17.

Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.

Zhao MH, Jayne DR, Ardiles LG, Culley F, Hodson ME, Lockwood CM.

QJM. 1996 Apr;89(4):259-65.

PMID:
8733512
18.

The role of myeloperoxidase and myeloperoxidase-antineutrophil cytoplasmic antibodies (MPO-ANCAs) in the pathogenesis of human MPO-ANCA-associated glomerulonephritis.

Arimura Y, Kawashima S, Yoshihara K, Komagata Y, Kaname S, Yamada A.

Clin Exp Nephrol. 2013 Oct;17(5):634-7. doi: 10.1007/s10157-013-0787-7. Review.

19.

Azurocidin-specific-ANCA-related idiopathic necrotizing crescentic glomerulonephritis.

Kimura R, Matsuzawa N, Arimura Y, Soejima A, Nakabayashi K, Yamada A.

Am J Kidney Dis. 2004 Apr;43(4):e7-10.

PMID:
15042565
20.
Items per page

Supplemental Content

Support Center